The FDA today repealed the emergency use authorization (EUA) it granted in March to anti-malarial drugs chloroquine phosphate and its less toxic metabolite hydroxychloroquine sulfate as treatments for COVID-19, citing a lack of consistent replication of arlier promising results and a randomized controlled clinical trial that showed no clinical benefit for hydroxychloroquine.
Hydroxychloroquine in particular became a household word in the weeks since the onset of the COVID-19 pandemic, after President Donald Trump first advocated its use in combination with azithromycin—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing. Last month, he disclosed that he had taken the drug to protect from infection with the SARS-CoV-2 virus.
Image: The FDA has repealed the emergency use authorization (EUA) it granted in March to anti-malarial drugs chloroquine phosphate and its less toxic metabolite hydroxychloroquine sulfate as treatments for COVID-19, citing a lack of consistent replication of earlier promising results and a randomized controlled clinical trial that showed no clinical benefit for hydroxychloroquine. (NIAID)
